Q1 Earnings Forecast for Kyntra Bio Issued By HC Wainwright

Kyntra Bio Inc (NASDAQ:KYNB) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Kyntra Bio in a report issued on Tuesday, March 17th. HC Wainwright analyst M. Keller anticipates that the company will post earnings of ($3.85) per share for the quarter. HC Wainwright has a “Strong-Buy” rating on the stock. HC Wainwright also issued estimates for Kyntra Bio’s Q2 2026 earnings at ($3.87) EPS, Q3 2026 earnings at ($4.00) EPS, Q4 2026 earnings at ($4.09) EPS, FY2026 earnings at ($15.80) EPS, FY2027 earnings at ($8.96) EPS and FY2028 earnings at ($8.89) EPS.

Several other brokerages have also recently commented on KYNB. Weiss Ratings assumed coverage on Kyntra Bio in a research note on Wednesday, January 14th. They issued a “sell (d+)” rating for the company. Zacks Research cut shares of Kyntra Bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

Kyntra Bio Price Performance

KYNB opened at $7.13 on Thursday. The stock has a market cap of $28.88 million, a P/E ratio of 0.16 and a beta of 0.84. Kyntra Bio has a fifty-two week low of $4.85 and a fifty-two week high of $12.60. The business’s 50-day moving average price is $7.74.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.